Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.

ABSTRACT:

Background

Hearts and lungs from donors with hepatitis C viremia are typically not transplanted. The advent of direct-acting antiviral agents to treat hepatitis C virus (HCV) infection has raised the possibility of substantially increasing the donor organ pool by enabling the transplantation of hearts and lungs from HCV-infected donors into recipients who do not have HCV infection.

Methods

We conducted a trial involving transplantation of hearts and lungs from donors who had hepatitis C viremia, irrespective of HCV genotype, to adults without HCV infection. Sofosbuvir-velpatasvir, a pangenotypic direct-acting antiviral regimen, was preemptively administered to the organ recipients for 4 weeks, beginning within a few hours after transplantation, to block viral replication. Th

SUBMITTER: Woolley AE 

PROVIDER: S-EPMC7369135 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature